… Results from randomized phase II studies suggest that adding cetuximab to first-line … This
multicenter, noncomparative, open-label, randomized phase II study was designed to evaluate …

… We report the final results of the randomized phase II study JO19907 in Japan, the only study
in Asia which compared the efficacy and safety of first-line CP with or without bevacizumab …

… This phase II noncomparative randomized trial was conducted to determine the optimal …
TRT), in patients with locally advanced unresected stage III non–small-cell lung cancer (NSCLC). …

… on chemotherapy for stage IV non-small-cell lung cancer. … Randomized phase III trial of
platinum-doublet chemotherapy … patients with advanced non-small-cell lung cancer: results of a …

… against many different tumor types. OAK (NCT02008227) is a randomized phase III study …
However, after the randomized phase II POPLAR study demonstrated survival benefit with …

Purpose This randomized phase II trial evaluated whether the combination of cisplatin and
paclitaxel (PC) plus all-trans retinoic acid (ATRA) increases response rate (RR) and …

… % in the standard arm and an acceptable toxicity in both arms; thus, criteria for extension
into phase III were met [10]. Here, we report the final analysis of the randomized phase III trial. …

… patients with advanced non–small-cell lung cancer (NSCLC) and poor performance status.
… This proof of principle randomized phase II study confirms that poor PS patients (PS 2 or 3) …

… To determine a standard combination chemotherapy for patients with advanced non-small-cell
lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the …

… Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum …
treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005; 104: 2766-2774 …